ADMA BIOLOGICS, INC. (ADMA) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001368514 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $124.4M | $37.8M | $0.16 | Filing |
| Mar 31, 2026 | May 6, 2026 | $114.5M | $45.3M | $0.19 | Filing |
| Dec 31, 2025 | Jan 12, 2026 | $139.2M | $49.4M | $0.20 | Filing |
| Sep 30, 2025 | Nov 5, 2025 | $134.2M | $36.4M | $0.15 | Filing |
| Jun 30, 2025 | Aug 6, 2025 | $122.0M | $34.2M | $0.14 | Filing |
| Mar 31, 2025 | May 7, 2025 | $114.8M | $26.9M | $0.11 | Filing |
| Dec 31, 2024 | Jan 13, 2025 | $117.5M | $111.9M | $0.45 | Filing |
| Sep 30, 2024 | Nov 7, 2024 | $119.8M | $35.9M | $0.15 | Filing |
What would ADMA BIOLOGICS, INC. have to report for its valuation to change?
At $10.68, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 5.5% a year, to $0.91. On that path the next quarter needs diluted EPS near $0.16, against $0.15 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 5.5% | 5.5% |
| EPS needed in final year | $0.91 | $0.91 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. ADMA goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.